These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 2252956
1. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms. Long GS, Cramer DV, Harnaha JB, Hiserodt JC. Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956 [Abstract] [Full Text] [Related]
2. Lymphokine-activated killer (LAK) cell purging of bone marrow. Cramer DV, Long GS. Prog Clin Biol Res; 1990 Sep; 333():125-35; discussion 136-7. PubMed ID: 2308977 [Abstract] [Full Text] [Related]
3. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Long GS, Hiserodt JC, Harnaha JB, Cramer DV. Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797 [Abstract] [Full Text] [Related]
9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A. J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200 [Abstract] [Full Text] [Related]
11. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. Gaiser JF, Kloosterman TC, Martens AC, Hagenbeek A. Leukemia; 1993 May 15; 7(5):736-41. PubMed ID: 8483327 [Abstract] [Full Text] [Related]
12. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant JP. Bone Marrow Transplant; 1995 May 15; 15(5):691-6. PubMed ID: 7670397 [Abstract] [Full Text] [Related]
13. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL, Herberman RB, Hiserodt JC. Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411 [Abstract] [Full Text] [Related]
18. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report. Tzeng CH, Chuang MW, Wang SY, Hsieh RK, Liu CJ, Fan S, Chen PM. Proc Natl Sci Counc Repub China B; 1990 Jan 15; 14(1):47-53. PubMed ID: 2381997 [Abstract] [Full Text] [Related]
19. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro. Kaneko T, Fukuda J, Teramura M, Fusauchi Y, Kakui Y, Okumura K, Mizoguchi H, Oshimi K. Bone Marrow Transplant; 1994 Aug 15; 14(2):213-7. PubMed ID: 7527685 [Abstract] [Full Text] [Related]
20. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. van den Brink MR, Voogt PJ, Marijt WA, van Luxemburg-Heys SA, van Rood JJ, Brand A. Blood; 1989 Jul 15; 74(1):354-60. PubMed ID: 2787676 [Abstract] [Full Text] [Related] Page: [Next] [New Search]